Tuesday, March 31, 2026 – Wednesday, April 1 - INDIANAPOLIS, March 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide)...
Tuesday, March 31, 2026 – Wednesday, April 1 - PLAINSBORO, N.J., March 31, 2026 /PRNewswire/ -- Novo Nordisk today announced a new multi-month subscription program for Wegovy® (semaglutide) that provides eligible self-pay patients who enroll in the program through select telehealth providers...
Tuesday, March 31, 2026 – Wednesday, April 1 - (MedPage Today) -- GLP-1 medications showed a range of potential benefits and safety concerns in an umbrella review of non-cardiometabolic outcomes, though the data quality for many remained limited.
Across 60 meta-analyses that assessed 116 non...
Tuesday, March 31, 2026 – TUESDAY, March 31, 2026 -- For adults with type 2 diabetes, discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with an increased risk for major adverse cardiovascular events, according to a study published online...
Tuesday, March 31, 2026 – Wednesday, April 1 - (MedPage Today) -- The PREVENT-TAHA8 intracoronary stem cell trial from Iran was officially retracted by The BMJ, months after an expression of concern was first published.
Poor diet remains a leading contributor to ischemic heart disease, with...
Tuesday, March 31, 2026 – Wednesday, April 1 - (MedPage Today) -- A 6-month hiatus in GLP-1 drug use was linked with an increased risk of major adverse cardiovascular events in patients with type 2 diabetes compared with continued use, according to a target trial emulation. (BMJ Medicine)...
Tuesday, March 31, 2026 – Wednesday, April 1 - A nascent biotech in the suburbs of Denver has convinced investors to commit $100 million to develop an oral small molecule in one of the most competitive fields in drug development.
Ambrosia Biosciences snagged the ...
Tuesday, March 31, 2026 – Wednesday, April 1 - Novo Nordisk is unveiling a subscription model for self-pay customers of its popular GLP-1 weight loss drug Wegovy with much lower prices for both the injectable and the pill through three telehealth services. It’s the latest effort by drug makers to reduce prices which includes partnering with big box stores to entice more patients. NBC’s Anne Thompson reports for TODAY.
Tuesday, March 31, 2026 – Tuesday, March 31 - You can now pay for Wegovy shots and pills just like you pay for an Amazon Prime subscription.
Novo Nordisk said patients paying cash can opt for 3-month, 6-month and yearlong subscriptions, securing a lower ...
Monday, March 30, 2026 – Tuesday, March 31 - (MedPage Today) -- DENVER -- Adding a GLP-1 agonist to psoriasis medication significantly improved outcomes in patients with psoriatic arthritis (PsA) and overweight or obesity, a phase III randomized trial showed.
After 36 weeks, almost a third...